PRESS & NEWS
Two Drugs Selected for New PSP Platform Trial
The Association for Frontotemporal Degeneration (AFTD) has shared that two drugs have been selected for evaluation in a new platform trial aimed at accelerating the development of treatments for progressive supranuclear palsy (PSP).
The Association for Frontotemporal Degeneration (AFTD) has shared that two drugs – AADvac1 and AZP2006 – have been selected for evaluation in a groundbreaking platform trial aimed at accelerating the development of treatments for progressive supranuclear palsy (PSP), one of the movement-related FTD disorders.
The trial is being conducted by researchers at the University of California, San Francisco; the University of California, San Diego; and Massachusetts General Hospital. It marks a significant milestone in the search for effective treatments for PSP. Enrollment for this PSP Platform Trial is expected to begin in late 2025
“The selection of these two promising drugs represents real momentum in PSP research,” said Carrie Milliard, Director of the FTD Disorders Registry. “The Registry is committed to connecting individuals with opportunities like this one, which have the potential to advance urgently needed treatments.”
To stay informed about this and other clinical trials, we encourage you to join the FTD Disorders Registry. Registry members receive updates on trials actively seeking participants and other research opportunities.
For updates specific to the PSP Platform Trial, visit CurePSP’s website.
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.